ReviewAdvances in enzyme regulation2010
Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.
Review in Advances in enzyme regulation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma.Journal of oncology · 2023Article
- Review
- MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.EBioMedicine · 2019Article
- Gli1, a potential cancer stem cell marker, is strongly associated with prognosis in prostate cancer.International journal of clinical and experimental pathology · 2018Article
- Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.Frontiers in pharmacology · 2018Review
- Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.Oncotarget · 2017Article
- Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.Oncotarget · 2016Article
- Article
- Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer.Cell cycle (Georgetown, Tex.) · 2015Article
- MicroRNAs targeting prostate cancer stem cells.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Soy isoflavones and prostate cancer: a review of molecular mechanisms.The Journal of steroid biochemistry and molecular biology · 2014Review
- GSK-3β: a key regulator of breast cancer drug resistance.Cell cycle (Georgetown, Tex.) · 2014Article
- Cancer stem cell theory: therapeutic implications for nanomedicine.International journal of nanomedicine · 2013Review
- Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action.PloS one · 2013Article
- Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.Cell cycle (Georgetown, Tex.) · 2011Article
- Article
- Review
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Oncotarget · 2011Review
- GnRH signaling, the gonadotrope and endocrine control of fertility.Frontiers in neuroendocrinology · 2010Review
- The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Cell cycle (Georgetown, Tex.) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.